ITMCTR2100004924招募中1 期
A randomized, double-blind, controlled clinical study on the intervention of Shudi Suoyang Decoction granule in PF-ILD with kidney essence deficiency syndrome
Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University0 个研究点开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 年龄范围
- 18 至 80（—）
- 性别
- All
入选标准
- •1.Aged 18 to 80 years;
- •2.PF-ILD diagnostic criteria of wetern medicine
- •Referring to internal medicine (8th Edition), practical interstitial lung disease (2nd Edition, people's Health Publishing House), IIP new international multidisciplinary classification of non IPF interstitial lung disease revised by ATS / ERS in 2013, and PF-ILD literature review, the clinical diagnostic characteristics are as follows:
- •(1)The symptoms were chronic cough, progressive dyspnea and decreased activity tolerance.
- •(2)Pulmonary auscultation and crackling sound with or without clubbed fingers, combined with connective tissue diseases can have the corresponding manifestations of primary disease, such as rash, joint pain, joint swelling, Raynaud's phenomenon and so on;
- •(3)The diagnosis of ILD can meet one of the following requirements: idiopathic pulmonary fibrosis (IPF), hypersensitive pneumonia (HP), autoimmune disease-related ILDs (including rheumatoid arthritis related interstitial lung disease, systemic sclerosis related interstitial lung disease and mixed connective tissue disease-related interstitial lung disease), idiopathic non-specific interstitial pneumonia (ISIP) Unclassified idiopathic interstitial pneumonia (unclassified IIP) and other ILDs (including sarcoidosis, environment related ILDs, fibrous ILDs caused by other causes);
- •(4)Chest HRCT showed diffuse abnormal changes in both lungs, mainly manifested as honeycomb shadow, grid shadow, tractive bronchodilation shadow, with or without ground glass shadow, whose area should be less than the grid area.
- •(5)Pulmonary fibrosis like changes caused by pulmonary infection and tumor diseases were excluded.
- •(6)Under the condition of treatment, one of the following conditions can be met within 24 months:
- •1)Relative decrease of forced vital capacity (FVC) >= 10%;
- •2)The relative decrease of FVC was more than 5%, and the absolute decrease of the predicted percentage of carbon monoxide dispersion capacity (DLCO) was more than 15%;
- •3)The relative decrease of FVC was more than 5%, and HRCT showed increased fibrosis (according to the evaluation of imaging experts);
- •4)FVC relative decrease >= 5% with aggravation of respiratory symptoms;
- •5)Aggravation of respiratory symptoms with progressive performance on HRCT (according to the evaluation of imaging experts).
- •(7)At present, there is no strict and unified disease diagnosis, this study only according to the international general diagnostic standards for western medicine disease diagnosis.
- •3.Pulmonary function test: FVC (forced vital capacity) predicted value >= 45%, and DLCO sb (carbon monoxide dispersion volume) >= 30% and < 80%;
- •4.PF-ILD diagnostic criteria of TCM Syndromes
- •Referring to the Chinese medicine industry standard of the people's Republic of China - diagnosis standard of TCM syndrome, combined with the case observation and clinical diagnosis and treatment experience of the research group in recent 7 years, it is found that the TCM syndrome of PF-ILD is mainly kidney essence deficiency syndrome, and the specific diagnostic characteristics are as follows: cough less phlegm, white sputum color, aggravation of peculiar smell after activity; Short breath, especially difficult to inhale, shallow breathing, aggravation of movement, mental fatigue, or fatigue, waist and knee soreness, chilly limbs, frequent urination, or nocturia, or cough enuresis, tongue light dark, mossy white, pulse thin slow weakness, especially in the ulna. The dia
排除标准
- •1.Pregnant or lactating women, or preparing for pregnancy during treatment;
- •2.Allergic to therapeutic drugs or components of therapeutic drugs;
- •3.They were complicated with chronic obstructive pulmonary disease, asthma, pulmonary embolism, etc.;
- •4.Patients with severe primary diseases, such as severe cardiac insufficiency, liver and kidney dysfunction, hematopoietic system disorders, tumors of various organs, as well as psychiatric history and communication difficulties;
- •5.There is clinical evidence of active infection, such as acute bronchitis, pneumonia, urinary tract infection, acute gastroenteritis or cellulitis;
- •6.Unable to cooperate with lung function test;
- •7.Patients have participated in other drug clinical trials or within one month;
- •8.During acute exacerbation of interstitial lung disease (AE).
研究者
相似试验
尚未招募
1 期
A randomized, double-blind, controlled clinical study on the effectiveness and safety of Gualou Guanxin Mixture in the treatment of coronary heart disease angina pectoris (qi deficiency and blood stasis syndrome)ITMCTR2000003759Shanghai Municipal Hospital of Traditional Chinese Medicine
尚未招募
Unknown
A randomized double-blind controlled study of Shuhe Granules in treating heart and kidney deficiency and Qi and blood disharmony syndrome of chronic insomnia disorderinsomniaITMCTR2023000013Guangdong Provincial hospital of Traditional Chinese Medicine
招募中
1 期
A randomized, controlled, double-blind clinical study of Jiawei Qilang Decoction in the treatment of drug dependent constipatiodrug dependent constipationITMCTR2000003862Shanghai Municipal Hospital of Traditional Chinese Medicine
尚未招募
2 期
A randomized, double-blind, controlled clinical trial of Suhe Granules for chronic insomnia patients with Disharmony of Qi and Blood and Deficiency of Heart and KidneyinsomniaITMCTR2200006603Guangdong Provincial Hospitai of Chinese Medicine
进行中（未招募）
不适用
A clinical trial to assess the Efficacy and safety of liposomal Curcumin in subjects with metabolic syndromeCTRI/2017/06/008903CureSupport